✦ LIBER ✦

Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies

✍ Scribed by J.H.M. Schellens; B. Heinrich; M. Lehnert; M.E. Gore; S.B. Kaye; P. Dombernowsky; R. Paridaens; A.T. van Oosterom; J. Verweij; W.J. Loos; H. Calvert; N. Pavlidis; H. Cortes-Funes; J. Wanders; M. Roelvink; C. Sessa; K. Selinger; P.S. Wissel; T. Gamucci; A.R. Hanauske

Book ID: 110329083
Publisher: Springer US
Year: 2002
Tongue: English
Weight: 112 KB
Volume: 20
Category: Article
ISSN: 0167-6997
DOI: 10.1023/a:1014454821885

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of the

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin

✍ Jong, R S de; Vries, E G E de 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 107 KB

Phase I and pharmacokinetic study of a l

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia

✍ Francis J. Giles; Martin S. Tallman; Guillermo Garcia-Manero; Jorge E. Cortes; D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Abstract ## BACKGROUND OSI‐211 is a low‐clearance, unilamellar liposomal formulation of a water‐soluble camptothecin analogue, lurtotecan. OSI‐211 has significant activity in severe combined immunodeficient mouse models of human leukemia. ## METHODS This study was conducted to define the dose

Phase I and pharmacokinetic study of DAC

Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II

✍ Twelves, C J; Gardner, C; Flavin, A; Sludden, J; Dennis, I; Bono, J de; Beale, P 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 92 KB

Phase II study of XR 5000, an inhibitor

Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer

✍ F Caponigro; C Dittrich; J.B Sorensen; J.H.M Schellens; F Duffaud; L Paz Ares; D 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 89 KB

A phase I study of the safety and pharma

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors

✍ Herbert I. Hurwitz; Roger B. Cohen; J. Patrick McGovren; Samit Hirawat; William 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 308 KB

Phase I and pharmacokinetic study of XR1

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1–5 of a 3-weekly cycle in patients with advanced solid tumours

✍ de Jonge, M J A; Kaye, S; Verweij, J; Brock, C; Reade, S; Scurr, M; van Doorn, L 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 127 KB